Clinical trials: Pancreatic Fibrosis
Cystic Fibrosis, Cystic Fibrosis in Children
Program Of Exercises During The Hospitalization Of Children And Adolescents With Cystic Fibrosis
The objective of this study was to evaluate the effect of a physical exercise program on the functional capacity of children and adolescents with cystic fibrosis hospitalized at the Hospital de Clínicas of Porto Alegre (HCPA)…
- Conditions
- Cystic Fibrosis, Cystic Fibrosis in Children, Cystic Fibrosis Pulmonary Exacerbation, Cystic Fibrosis With Exacerbation
- Trial name
- NCT03273959
- Testing
- Exercise protocol
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Inflammatory Changes in Epithelial Lining Fluid Sampled Non-invasively by Nasal Lavage in CF Patients With G551D Receiving Kalydeco
Effects of Kalydeco on Upper Airway and Paranasal Sinus Inflammation Measured by Nasal Lavage and on Symptoms
The aim of the proposed trial in assessment of effects of Kalydeco™ treatment on sinonasal involvement in CF patients with at least one mutation of G551D receiving a new therapy with the CFTR potentiator.
- Trial name
- KPNSI (NCT02311140)
- Testing
- nasal lavage (routine diagnostic procedure in our centre), assessment of symptoms
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- University of Jena
Cystic Fibrosis, Contraception
MyVoice:CF Decision Aid for Women With Cystic Fibrosis
This project is a single-center feasibility study of MyVoice:CF, a patient-facing, web-based decision aid. Aim 1) Assess the acceptability, feasibility, and usability of MyVoice:CF for women with CF and multidisciplinary adult CF…
- Conditions
- Cystic Fibrosis, Contraception, Physician-Patient Relations, Pregnancy Complications
- Trial name
- NCT04825236
- Testing
- MyVoice:CF
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Pittsburgh
Cystic Fibrosis
Aztreonam Lysine for Pseudomonas Infection Eradication Study
This is an open-label, multi-center study in pediatric patients age 3 months to less than 18 years with cystic fibrosis (CF) and newly detected Pseudomonas aeruginosa (PA) pulmonary colonization/infection.
- Trial name
- ALPINE (NCT01375049)
- Testing
- Aztreonam for Inhalation Solution (AZLI)
- Where
- 58 sites in United States, Austria and 7 more
- Volunteers
- 105 people
- Sponsor
- Gilead Sciences
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Assessment of a PERT-free Nutritional Therapeutic Delivery System for Cystic Fibrosis
This is a single center, randomized, double-blind, cross-over trial (with a follow-on single-blind safety evaluation stage), assessing a ready-to-drink nutritional supplement used without PERT ("PERT-free"), nutritional…
- Trial name
- NCT04966897
- Testing
- Standard Nutritional Supplement + PERT
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- GlycosBio, Inc.
Staphylococcus Aureus
Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs
Patients who are at least 7 years old with stable Cystic Fibrosis who have Staphylococcus aureus in their Lungs will be enrolled into the study and receive one dose of Aurexis® intravenously on Study Day 1, and will be followed…
- Trial name
- NCT00198289
- Testing
- Aurexis® (tefibazumab)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Bristol-Myers Squibb
Cystic Fibrosis, Bronchiectasis
Prevention of Bronchiectasis in Infants With Cystic Fibrosis
The general aim of this project is to conduct a randomized, double-blind, placebo-controlled clinical trial of azithromycin to determine whether treatment from infancy is safe and will prevent the onset of bronchiectasis.
- Trial name
- COMBATCF (NCT01270074)
- Testing
- Azithromycin
- Where
- 10 sites in Australia, New Zealand
- Volunteers
- 130 people
- Sponsor
- The University of Queensland
Cystic Fibrosis
Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy
Despite the increasingly common use of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies in treating CF, it is still largely unknown whether or not other chronic therapies can be safely stopped.
- Trial name
- SIMPLIFY (NCT04378153)
- Where
- 80 sites in United States
- Volunteers
- 987 people
- Sponsor
- Nicole Hamblett
Mesothelioma, Lung Neoplasms
Chest Wall Motion Analysis in Disease
Breathing movements, called chest wall motion, are very complex. The investigators are studying how movement of the abdomen, ribs and diaphragm contribute to breathing and how this differs with different diseases in the chest.
- Conditions
- Mesothelioma, Lung Neoplasms, Surgery, Cystic Fibrosis
- Trial name
- CWM (NCT02958683)
- Testing
- Chest wall motion analysis
- Where
- United Kingdom
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Heart of England NHS Trust
Cystic Fibrosis
Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects
The purpose of this study is to assess the pharmacokinetics and safety of co-administration of VX-770 and VX-809 in healthy adults.
- Trial name
- NCT00966602
- Testing
- VX-809, VX-770, VX-809 & VX-770
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
ENHANCE- Establishing Natural History in an Advanced New CF Care Era
Measured outcomes for people with CF have improved dramatically over the last 20 years, even prior to the widespread introduction of cystic fibrosis transmembrane conductance regulator (CTFR) modulator treatments.
- Trial name
- NCT05986045
- Testing
- Quality of Life
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Royal College of Surgeons, Ireland
Cystic Fibrosis, Pseudomonas Aeruginosa
Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization
The purpose of this study is to determine whether the nasal inhalation of Gernebcin® is effective to decrease the Pseudomonas aeruginosa bacterial count in the nasal lavage fluid.
- Trial name
- NCT00774072
- Testing
- Tobramycin (Gernebcin®)
- Where
- 2 sites in Germany
- Volunteers
- 9 people
- Sponsor
- University of Jena
Cystic Fibrosis Homozygous for Phe 508 Del CFTR, Glucose Intolerance or Newly Diagnosis Diabetes
Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor
Cystic Fibrosis related diabetes (CFRD), a major factor of morbid-mortality in CF, is characterized by a preclinical phase of glucose intolerance particularly long reaching up to 10 years.
- Trial name
- GLUCORRECTOR (NCT03512119)
- Testing
- Lumacaftor-Ivacaftor treatment
- Where
- 13 sites in France
- Volunteers
- 55 people
- Sponsor
- University Hospital, Strasbourg, France
Cystic Fibrosis
A Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeat Doses of Inhaled ETD001 in People With Cystic Fibrosis
This study is the first to give ETD001 to people with CF. The study will be run in two parts. Part A will assess if ETD001 is safe to give to people with CF, and Part B will assess if ETD001 improves lung function.
- Trial name
- NCT06478706
- Testing
- ETD001
- Where
- 21 sites in France, Germany and 2 more
- Volunteers
- 57 people
- Sponsor
- Enterprise Therapeutics Ltd
Cystic Fibrosis
Intermittent Versus Continuous Infusion Meropenem in Cystic Fibrosis
The purpose of this study is to compare the incidence of nausea and vomiting following short intermittent versus prolonged intermittent infusion of meropenem.
- Trial name
- NCT02048163
- Where
- United States
- Sponsor
- Dayton Children's Hospital
Cystic Fibrosis
Identification of Predictive Epigenetic Biomarkers of Lung Disease Severity in Cystic Fibrosis
The general aims of this project are (i) to identify predictive epigenetic biomarkers of lung disease severity in Cystic Fibrosis, (ii) to characterize a non-invasive cellular model, spontaneous sputum, for the analysis of these…
- Trial name
- MethylBiomark (NCT02976714)
- Testing
- spontaneous sputum
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Montpellier
Cystic Fibrosis, Chronic Rhinosinusitis
Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis
Rhinosinusitis disorders are often associated with Cystic Fibrosis. They can restrict quality of life enormously and give cause to repeated ENT surgery.
- Trial name
- NCT00265434
- Testing
- Pulmozyme
- Where
- Germany
- Volunteers
- 5 people
- Sponsor
- University of Jena
Cystic Fibrosis, Oxidative Stress
Flaxseed Modulates Inflammation and Oxidative Stress in CF
Flaxseed (FS) is a safe and well tolerated supplement with an ability to fight inflammation and oxidative stress - a byproduct of daily stress the human body faces everyday and especially with chronic diseases.
- Conditions
- Cystic Fibrosis, Oxidative Stress, Inflammation
- Trial name
- NCT02014181
- Testing
- finely ground flaxseed powder
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Respiratory Tract Diseases, Abnormal Mucus Secretions
A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions
This is a phase 3, multicenter, randomized, rater- and patient-blind, placebo- and active-controlled, 3-arm parallel group clinical trial.
- Trial name
- NCT03843541
- Testing
- N-acetylcysteine (NAC) 600 mg, Ambroxol hydrochloride 30 mg
- Where
- 32 sites in China
- Volunteers
- 333 people
- Sponsor
- Zambon SpA
Cystic Fibrosis
Extension Study of Ataluren (PTC124) in Cystic Fibrosis
Cystic fibrosis (CF) is a genetic disorder caused by a mutation in the gene that makes the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
- Trial name
- NCT01140451
- Testing
- Ataluren
- Where
- 31 sites in United States, Belgium and 9 more
- Volunteers
- 191 people
- Sponsor
- PTC Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.